-

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences.

  • Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28.
  • Jefferies Global Healthcare Conference 2025 in New York, NY. Presentation on Thursday, June 5 at 10:30 a.m. ET.
  • Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. Fireside chat on Monday, June 9 at 3:20 p.m. ET.

To listen to the webcast for the June 5th and June 9th events, please visit the Events & Presentations section of CareDx’s Investor Relations website at: www.investors.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Contacts

Investor Relations
Caroline Corner
investor@caredx.com

CareDx, Inc.

NASDAQ:CDNA

Release Versions

Contacts

Investor Relations
Caroline Corner
investor@caredx.com

More News From CareDx, Inc.

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world...

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an agg...

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company’s Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company’s finance organization effective...
Back to Newsroom